GALAPAGOS NV
GLPGF$3.21B
Mid CapNASDAQBiotechnology🇺🇸North America704 employees
Drugs in Pipeline
5
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
GLPGF News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
Filgotinib
Rheumatoid Arthritis
GLPG3667
Systemic Lupus Erythematosus
GLPG0634
Crohn's Disease
GLPG1205
Ulcerative Colitis
GLPG3970
Ulcerative Colitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Filgotinib | Phase 2 | Rheumatoid Arthritis | - | - |
GLPG3667 | Phase 2 | Systemic Lupus Erythematosus | - | - |
GLPG0634 | Phase 2 | Crohn's Disease | - | - |
GLPG1205 | Phase 2 | Ulcerative Colitis | - | - |
GLPG3970 | Phase 2 | Ulcerative Colitis | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply